Education
About Us
Working with TipRanks
Follow Us
Kenvue, Inc. (KVUE)
NYSE:KVUE
KVUE Stock Chart & Stats
$17.80
-$0.04(-0.19%)
At close: 4:00 PM EST
$17.80
-$0.04(-0.19%)
Day’s Range― - ―
52-Week Range$14.02 - $25.17
Previous CloseN/A
Volume2.33M
Average Volume (3M)35.38M
Market Cap
$33.80B
Enterprise Value$41.77B
Total Cash (Recent Filing)$1.14B
Total Debt (Recent Filing)$9.11B
Price to Earnings (P/E)23.9
Beta<0.01
Next Earnings
Feb 05, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend Yield4.85%
Share Statistics
EPS (TTM)0.28
Shares Outstanding1,916,011,600
10 Day Avg. Volume46,431,205
30 Day Avg. Volume35,382,956
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)4.20
Price to Sales (P/S)2.62
P/FCF Ratio30.38
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue2.78
Enterprise Value/Gross Profit4.79
Enterprise Value/Ebitda14.20
Forecast
1Y Price Target
$19.00Price Target Upside6.74% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Brand And Operational TurnaroundImproving results in the skin health and beauty portfolio, including gains at Neutrogena, combined with cost savings and targeted marketing investments, support a return to balanced growth.
Legal Defense ProgressCurrent court posture limits Kenvue's acetaminophen exposure to legal fees rather than damages, reducing immediate financial downside.
Strategic TransactionAgreement to be acquired by Kimberly-Clark in a cash-and-stock transaction offers a clear strategic path that could crystallize value for shareholders.
Bears Say
Appeal And Litigation OverhangAppellate court signals that plaintiffs' expert testimony may be allowed and judges' questioning could lead to remand, increasing the prospect of a prolonged legal battle.
Reputational And Demand RiskOngoing negative headlines and regulatory scrutiny about acetaminophen and talc have the potential to erode consumer trust and accelerate shifts away from core products.
Soft Financial PerformanceSluggish quarterly results and weaker-than-expected organic sales indicate operational headwinds that could depress near-term revenue and investor confidence.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $14.02 and its highest was $25.17 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $33.80B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Feb 05, 2026 which is in 9 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Sep 28, 2025. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.02.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Undervalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Quarterly dividend of $0.207 which represents an annual dividend yield of 4.85%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.22.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,916,011,600 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of $0.26. Following the earnings report the stock price went up 2.203%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kenvue, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.00 (6.74% Upside)
$19.00 (6.74% Upside)
Blogger Sentiment
Bullish
KVUE Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 23.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $111.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.66%
12-Months-Change
Fundamentals
Return on Equity
13.47%
Trailing 12-Months
Asset Growth
1.20%
Trailing 12-Months
Company Description
Kenvue, Inc.
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.23% Self Care
27.43% Skin Health and Beauty
30.33% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
$19.00
▲(6.74% Upside)
Technical Analysis
Ownership Overview
1.47% Insiders
28.86% Mutual Funds
0.37% Other Institutional Investors
40.04% Public Companies and Individual Investors